Hi Karl
 
I have tested the impact of having exp(-16) or exp(-32) in the last line of SPM_PEB.m and it did not make the slightest bit of difference to the results of my PPI analyses. I have confirmed this on two seperate PPIs - the SPM was identical in both cases.
  
All the best,
 
Richard

On Thu, Mar 17, 2011 at 11:38 AM, Karl Friston <[log in to unmask]> wrote:
Dear Donald,

Making this change should have a trivial impact on the results - it is just to regularize
the inversion. You can regard the speye(length(C))*exp(-16) as a very uninformative
augmentation of the prior precision

I have just checked our development code and we do indeed use  speye(length(C))*exp(-16).
In future, we will use spm_inv - see below.

With very best wishes,

Karl





function X = spm_inv(A,TOL)
% inverse for ill-conditioned matrices
% FORMAT X = spm_inv(A)
%
% A  - matrix
% X  - inverse
%
% This routine simply adds a small identity matrix to A and calls inv.m
%__________________________________________________________________________
% Copyright (C) 2008 Wellcome Trust Centre for Neuroimaging
 
% Karl Friston
% $Id: spm_inv.m 4098 2010-10-22 19:46:28Z karl $
 
% check A
%--------------------------------------------------------------------------
[m,n] = size(A);
if isempty(A), X = sparse(n,m); return, end
 
% tolerance
%--------------------------------------------------------------------------
TOL = max(eps(norm(A, 'inf' ))*max(m,n),exp(-32));
 
% inverse
%--------------------------------------------------------------------------
X   = inv(sparse(A) + speye(m,n)*TOL);





At 04:03 17/03/2011, MCLAREN, Donald wrote:
Karl,

I've noticed a number of posts recently about changing the following line in spm_PEB.m to avoid warning messages:
line 371 from C  = inv(C + speye(length(C))*exp(-32)); to C  = inv(C + speye(length(C))*exp(-16));

(1) Does this change make a large impact on the analyses?
(2) Are there plans to implement the change in future versions?
(3) Should it be changed?

Best Regards, Donald McLaren
=================
D.G. McLaren, Ph.D.
Postdoctoral Research Fellow, GRECC, Bedford VA
Research Fellow, Department of Neurology, Massachusetts General Hospital and Harvard Medical School
Office: (773) 406-2464
=====================
This e-mail contains CONFIDENTIAL INFORMATION which may contain PROTECTED HEALTHCARE INFORMATION and may also be LEGALLY PRIVILEGED and which is intended only for the use of the individual or entity named above. If the reader of the e-mail is not the intended recipient or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that you are in possession of confidential and privileged information. Any unauthorized use, disclosure, copying or the taking of any action in reliance on the contents of this information is strictly prohibited and may be unlawful. If you have received this e-mail unintentionally, please immediately notify the sender via telephone at (773) 406-2464 or email.